GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rapid Therapeutic Science Laboratories Inc (OTCPK:RTSL) » Definitions » Interest Coverage

Rapid Therapeutic Science Laboratories (Rapid Therapeutic Science Laboratories) Interest Coverage : 0 (At Loss) (As of Jun. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Rapid Therapeutic Science Laboratories Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Rapid Therapeutic Science Laboratories's Operating Income for the three months ended in Jun. 2023 was $-0.10 Mil. Rapid Therapeutic Science Laboratories's Interest Expense for the three months ended in Jun. 2023 was $-0.06 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Rapid Therapeutic Science Laboratories's Interest Coverage or its related term are showing as below:


RTSL's Interest Coverage is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 18.22
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Rapid Therapeutic Science Laboratories Interest Coverage Historical Data

The historical data trend for Rapid Therapeutic Science Laboratories's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Rapid Therapeutic Science Laboratories Interest Coverage Chart

Rapid Therapeutic Science Laboratories Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Rapid Therapeutic Science Laboratories Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.38 - -

Competitive Comparison of Rapid Therapeutic Science Laboratories's Interest Coverage

For the Medical Devices subindustry, Rapid Therapeutic Science Laboratories's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rapid Therapeutic Science Laboratories's Interest Coverage Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Rapid Therapeutic Science Laboratories's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Rapid Therapeutic Science Laboratories's Interest Coverage falls into.



Rapid Therapeutic Science Laboratories Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Rapid Therapeutic Science Laboratories's Interest Coverage for the fiscal year that ended in Dec. 2022 is calculated as

Here, for the fiscal year that ended in Dec. 2022, Rapid Therapeutic Science Laboratories's Interest Expense was $-1.90 Mil. Its Operating Income was $-1.26 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.43 Mil.

Rapid Therapeutic Science Laboratories did not have earnings to cover the interest expense.

Rapid Therapeutic Science Laboratories's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Here, for the three months ended in Jun. 2023, Rapid Therapeutic Science Laboratories's Interest Expense was $-0.06 Mil. Its Operating Income was $-0.10 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.39 Mil.

Rapid Therapeutic Science Laboratories did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Rapid Therapeutic Science Laboratories  (OTCPK:RTSL) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Rapid Therapeutic Science Laboratories Interest Coverage Related Terms

Thank you for viewing the detailed overview of Rapid Therapeutic Science Laboratories's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Rapid Therapeutic Science Laboratories (Rapid Therapeutic Science Laboratories) Business Description

Traded in Other Exchanges
N/A
Address
5580 Peterson Lane, Suite 120, Dallas, TX, USA, 75201
Rapid Therapeutic Science Laboratories Inc is a biotech company specializing in natural-based relief through aerosol delivery of cannabinoids to the systemic bloodstream through the pulmonary route of administration. The company manufactures its own branded metered dose inhalers (MDI) under the nhaler name using proprietary blends of pure cannabinoids such as cannabidiol (CBD) and cannabigerol (CBG). In addition, the company manufactures other aerosol devices for the delivery of cannabinoids other than MDI such as sublingual sprays.
Executives
Henry Anthony Punzi director 1932 WALNUT PLAZA, CARROLLTON TX 75006
Scott Suggs Justin director 639 SWORD BRIDGE DR., LEWISVILLE TX 75056
Sean Paul Berrier 10 percent owner 7108 DUFFIELD DR., DALLAS TX 75248
Schmidt Donal Ray Jr. director, 10 percent owner, officer: President and CEO 5580 PETERSON LANE, SUITE 200, DALLAS TX 75240
Ryan Casey Johnson director, officer: Chief Operating Officer 2307 CASTLE ROCK RD, CARROLTON TX 75007
Texas Mdi, Inc. 10 percent owner 5580 PETERSON LANE, SUITE 200, DALLAS TX 75240
D Hughes Watler director, officer: CFO 2323 S. VOSS ROAD, STE. 510-12, HOUSTON TX 77057
Steve Bond director, officer: CFO 28839 PUJOL ST., #832, TEMECULA CA 92590
Brent Willson director, officer: CEO and President 5271 CAMINITO EXQUISITO, SAN DIEGO CA 92130